The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Review and analysis of FDA approved drugs using lipid-based formulations
Open accessAbstract
Lipid-based drug delivery systems (LBDDS) are one of the most studied bioavailability enhancement technologies and are utilized in a number of U.S. Food and Drug Administration (FDA) approved drugs. While researchers have used several general rules of thumb to predict which compounds are likely to benefit from LBDDS, formulation of lipid systems is primarily an empiric endeavor. One of the challenges is that these rules of thumb focus in different areas and are used independently of each other. The Developability Classification System attempts to link physicochemical characteristics with possible formulation strategies. Although it provides a starting point, the formulator still has to empirically develop the formulation. This article provides a review and quantitative analysis of the molecular properties of these approved drugs formulated as lipid systems and starts to build an approach that provides more directed guidance on which type of lipid system is likely to be the best for a particular drug molecule.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With numerous commercial successes, lipid-based drug delivery systems (LBDDS) have a proven track record to improve oral absorption of poorly water-soluble drugs (PWSDs) through a variety of mechanisms including increasing solubility, reducing food-induced exposure variability and improving overall intestinal uptake (Savla et al., 2017).”
From Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across PermeapadⓇ membrane and in vivo absorption (2020) · cites this paper as Savla et al., 2017
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
Solubilizing Excipients in Oral and Injectable Formulations
Strickley, R. G. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016235.32639.23 · Cited by 1,417
Pouton, C. W. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.04.016 · Cited by 1,306
(2017) · Arzneimittelforschung · doi:10.1055/s-00000175 · Cited by 1,134
Pouton, C. W., & Porter, C. J. H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.010 · Cited by 908
Research works printed but not linked: 11
- Porter CJH., 2007, Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs, 185
- Griffin B., 2012, Am Pharm Rev
- 10.1097/00007890-199559040-00011 · DOI
- Gao P. MW., 2007, Oral lipid-based formulations enhancing the bioavailability of poorly water soluble drugs
- Martins S, 2007, Int J Nanomed, 2, 595
- 2013, Abelcet®
- Johansen HK, 2014, Cochrane Database Syst Rev, CD000969
- Chen Y-C, 2015, Int J Nanomed, 10, 7265
- Zgair A, 2016, Am J Trans Res, 8, 3448
- Perlin DS., 2004, Curr Opin Investig Drugs, 5, 198
- Yang Z, 2014, Int J Nanomed, 9, 327
Cited by
Sorted by citations
Advances in Oral Drug Delivery
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618411 · Cited by 945
Azman, M., Sabri, A. H. B., Anjani, Q. K., Mustaffa, M. F., & Hamid, K. A. (2022) · Pharmaceuticals · doi:10.3390/ph15080975 · Cited by 277
Nguyen, T., Duong, V., & Maeng, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071103 · Cited by 272
Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems
Moreno‐Alcántar, G., Picchetti, P., & Casini, A. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202218000 · Cited by 207
Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs
Nyamba, I., Sombié, C. B., Yabré, M., Zimé-Diawara, H., Yaméogo, J. B. G., Ouédraogo, S., Lechanteur, A., Semdé, R., & Évrard, B. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114513 · Cited by 188
Metadata
- Authors
- Savla, R., Browne, J., Plassat, V., Wasan, K. M., & Wasan, E. K.
- Affiliations
- Catalent (United States) (US)
- Cerenis Therapeutics (France) (FR)
- University of Saskatchewan (CA)
- Corresponding author
- Savla, Ronak
- Venue
- Drug Development and Industrial Pharmacy
- Publisher
- Informa UK Limited
- Published
- 2017-07-06
- Volume
- 43
- Issue
- 11
- Pages
- 1743-1758
- ISSN
- 0363-9045 (ISSN-L)
- 1520-5762
- OpenAlex
- W2732877934
- Cited by
- 225
- References
- 75
- Citations by year
- 2026: 12 · 2025: 24 · 2024: 23 · 2023: 23 · 2022: 27 · 2021: 39 · 2020: 42 · 2019: 21 · 2018: 14
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Drug Development and Industrial Pharmacy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (cc-by)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- lipid-based drug delivery, bioavailability enhancement, FDA-approved drugs, physicochemical properties, molecular properties
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Lipids, United States, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
